Reevaluation of lymphovascular invasion in gastric cancer using endothelial markers D2‐40 and EVG: Enhanced detection, better predictor of lymph node metastasis and biological aggressiveness. Issue 8 (26th March 2021)

• Record Type: Journal Article
• Authors: Liu, Jingdong; Li, Haojie; Zhou, Peng; Cai, Tianyi; Tang, Zhaoqing; Wang, Yan; Cui, Yuehong; Sun, Yihong; Wang, Xuefei
• Is Part Of: Journal of surgical oncology. Volume 123:Issue 8(2021)
• Page Start: 1736
• Page End: 1741
• Publication Date: 2021-03-26
• Subjects: biological aggressiveness -- gastric cancer -- immunohistochemistry -- lymph node metastasis -- lymphovascular invasion; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.26468
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background and Objectives: The diagnosis of lymphovascular invasion (LVI) is often inaccurate with routine histology. This study aimed to evaluate the use of immunohistochemistry (IHC) in detecting LVI and reevaluate the clinical implications of LVI in gastric cancer. Methods: This prospective unrandomized cohort study analyzed the rates of LVI positivity and its relevance with other clinicopathologic features. Results: Between November 2017 and April 2018, 558 patients undergoing curative gastrectomy were enrolled and assigned to the IHC group ( n = 285) and hematoxylin–eosin group ( n = 273). The use of IHC increased the rates of LVI positivity (60.8% vs. 43.3%, p < .001) and decreased the rates of undetermined LVI subtype (7.7% vs. 27.1%, p < .001). The LVI‐negative patients identified by IHC had fewer lymph node metastases (16.8% vs. 34.6%, p = .002) and earlier pathological stage ( p = .004) than those identified by routine histology. The LVI‐positive patients identified by IHC had a higher percentage of perineural invasion ( p = .019). Conclusions: The use of endothelial markers significantly enhanced the detection of LVI. The LVI detected by IHC could be a better predictor of lymph node metastasis and biological aggressiveness in gastric cancer.